Medtronic unveils SynchroMed advance in US:
This article was originally published in Clinica
Medtronic is to launch an extended life version of its SynchroMed implantable drug delivery system in the US market. The device has been used since 1988 to treat cancer and non-malignant chronic pain and to deliver drugs directly into fluid surrounding the spinal cord. The extended life version claims to extend the battery life of the system from four to seven years, with the capability of lower flow rates in order to use the device for a wider range of drugs.